ATAI News and Press, ATAI Life Sciences N.V. From 03/07/22

On April 7, 2021, Atai Life Sciences , (NASDAQ: ATAI) a clinical-stage biopharmaceutical company developing psychedelics and non-psychedelic compounds for mental health wellness, acquired a majority stake in Delaware-based Psyber , a company working on a brai...

NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response...

Numinus offers a lower risk exposure to the psychedelics space in comparison to stocks focused on drug discovery and development. Capital flows into the sector have not yet recognized the importance of the therapeutic delivery model. Numinus has a healthy cash balance, a solid ind...

- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health company, atai Life Sciences - Funds will help support the general operatio...

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February. ...

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central ner...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 –  After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes....

Psychedelics could be a game-changer in the treatment of mental health. So far, studies show how useful they can be in treating mental health issues, such as o bsessive compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety to name a few. Ketamine could help tr...

•  Enables expansion of PCN-101 clinical development to the U.S. •  atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs •  DDI tr...

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference today: ...